Clonazepam Tablet
NDC 70518-1801
Product Information
Clonazepam is a ANDA-approved product labeled by Remedyrepack Inc.. Clonazepam is used to prevent and control seizures. It is supplied as a orange tablet for oral administration. This product entry covers the primary NDC 70518-1801 and its associated package configuration. This profile includes active and inactive ingredient UNII references and FDA labeling data.
Primary Identification
Clinical Specifications
Labeler & Regulatory Data
Marketing Timeline
Product Characteristics
1;2
Code Structure Chart
Product Details
What is NDC 70518-1801?
What are the uses of this product?
What are Active Ingredients of this product?
- CLONAZEPAM .5 mg/1 - An anticonvulsant used for several types of seizures, including myotonic or atonic seizures, photosensitive epilepsy, and absence seizures, although tolerance may develop. It is seldom effective in generalized tonic-clonic or partial seizures. The mechanism of action appears to involve the enhancement of GAMMA-AMINOBUTYRIC ACID receptor responses.
Which are the associated UNII Codes?
The UNII codes for the active ingredients in this product are:
- CLONAZEPAM (UNII: 5PE9FDE8GB)
- CLONAZEPAM (UNII: 5PE9FDE8GB) (Active Moiety)
Which are the Inactive Ingredients associated UNII Codes?
The inactive ingredients are all the component of a medicinal product OTHER than the active ingredient(s). The acronym "UNII" stands for “Unique Ingredient Identifier” and is used to identify each inactive ingredient present in a product. The UNII codes for the inactive ingredients in this product are:
- ANHYDROUS LACTOSE (UNII: 3SY5LH9PMK)
- LACTOSE MONOHYDRATE (UNII: EWQ57Q8I5X)
- MAGNESIUM STEARATE (UNII: 70097M6I30)
- CELLULOSE, MICROCRYSTALLINE (UNII: OP1R32D61U)
- STARCH, CORN (UNII: O8232NY3SJ)
- FD&C YELLOW NO. 6 (UNII: H77VEI93A8)
What is the NDC to RxNorm Crosswalk for this product?
- RxCUI: 197527 - clonazePAM 0.5 MG Oral Tablet
- RxCUI: 197527 - clonazepam 0.5 MG Oral Tablet
Which are the Pharmacologic Classes of this product?
* Please review the full disclaimer at the bottom of this page.